FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Algernon Pharmaceuticals Inc. (the "Issuer").

Trading Symbol: AGN

Date: April 14, 2020

1. New Options Granted:

Date of Grant: April 13, 2020

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Chris Moreau	Officer	Y	1,250,000	$0.29	04/13/25	500,000
Mark Williams	Officer	Y	1,250,000	$0.29	04/13/25	500,000
Michael Sadhra	Director	Y	1,000,000	$0.29	04/13/25	1,000,000
David Levine	Director	Y	200,000	$0.29	04/13/25	200,000
Raj Attariwala	Director	Y	200,000	$0.29	04/13/25	200,000
Jeanie Yu	Consultant	N	50,000	$0.29	04/13/25	100,000
Alicia Milne	Consultant	N	25,000	$0.29	04/13/25	25,000
Michael Malana	Consultant	N	25,000	$0.29	04/13/25	25,000
Howard Guttman	Consultant	N	200,000	$0.29	04/13/25	Nil
Znek Holdings Ltd.	Consultant	N	250,000	$0.29	04/13/25	Nil
John Gubenco	Consultant	N	100,000	$0.29	04/13/25	Nil

Total Number of optioned shares proposed for acceptance: 4,550,000.

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares[(1)]	Exercise Price	Original Date of Grant	Expiry Date
Michael Sadhra	200,000	0.50	10/26/2015	02/01/2021
Raj Attariwala	125,000	0.50	10/26/2015	02/01/2021
David Levine	200,000	0.50	10/26/2015	02/01/2021
Michael Malana	12,500	0.50	10/26/2015	02/01/2021
Raj Attariwala	50,000	0.30	05/18/2017	05/18/2022
Kim Casswell	12,500	0.30	05/18/2017	05/18/2022
David Levine	50,000	0.30	05/18/2017	05/18/2022
Michael Sadhra	50,000	0.30	05/18/2017	05/18/2022
Jeanie Yu	25,000	0.30	05/18/2017	05/18/2022
Raj Attariwala	50,000	0.48	03/01/2018	03/01/2023
Kim Casswell	12,500	0.48	03/01/2018	03/01/2023
David Levine	50,000	0.48	03/01/2018	03/01/2023
Michael Malana	12,500	0.48	03/01/2018	03/01/2023
Chris Moreau	250,000	0.48	03/01/2018	03/01/2023
Michael Sadhra	150,000	0.48	03/01/2018	03/01/2023
Marjorie Winslow	12,500	0.48	03/01/2018	03/01/2023
Jeanie Yu	25,000	0.48	03/01/2018	03/01/2023
Kal Malhi	1,500,000	$0.10	02/13/2020	02/13/2025
Chris Moreau	500,000	$0.10	02/13/2020	02/13/2025
Mark Williams	500,000	$0.10	02/13/2020	02/13/2025
Michael Sadhra	1,000,000	$0.10	02/13/2020	02/13/2025
David Levine	200,000	$0.10	02/13/2020	02/13/2025
Raj Attariwala	200,000	$0.10	02/13/2020	02/13/2025
Jeanie Yu	100,000	$0.10	02/13/2020	02/13/2025
Alicia Milne	25,000	$0.10	02/13/2020	02/13/2025
Michael Malana	25,000	$0.10	02/13/2020	02/13/2025
Arun Sanyal	25,000	$0.10	02/13/2020	02/13/2025
Martin Kolb	25,000	$0.10	02/13/2020	02/13/2025
Walter Reinsch	25,000	$0.10	02/13/2020	02/13/2025
Mark Swaim	200,000	$0.10	02/13/2020	02/13/2025
Ed Lerfino	50,000	$0.10	02/13/2020	02/13/2025

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

The stock option plan was approved by shareholders on September 11, 2015

(b) State the date of the news release announcing the grant of options.

April 13, 2020

(c) State the total issued and outstanding share capital at the date of grant or amendment.

103,954,697

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options. 9.84%

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

There are 171,270 shares remaining reserved for issuance under the plan.

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

N/A .

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer. There are no proposed material changes in the affairs of the Issuer.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated April 14, 2020.

Michael Sadhra
Name of Director or Senior Officer

/s/ "Michael Sadhra"
Signature

Director
Official Capacity